Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALXO NASDAQ:AMRN NYSE:ANVS NASDAQ:SRZN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$1.93+1.9%$1.90$0.40▼$2.66$259.03M0.41847,838 shs337,325 shsAMRNAmarin$14.55+0.9%$14.57$11.27▼$20.90$305.01M0.8175,241 shs33,155 shsANVSAnnovis Bio$1.93+1.3%$2.09$1.54▼$5.50$66.70M1.26791,920 shs822,106 shsSRZNSurrozen$24.87-4.9%$28.72$7.60▼$35.00$289.84M0.59107,026 shs103,867 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology-3.57%-5.03%+15.24%-10.43%+321.78%AMRNAmarin-0.76%-0.96%+3.22%+4.42%+27.64%ANVSAnnovis Bio-5.46%-11.60%+1.60%-29.18%-21.28%SRZNSurrozen-1.13%-3.43%-15.56%-5.90%+231.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$1.93+1.9%$1.90$0.40▼$2.66$259.03M0.41847,838 shs337,325 shsAMRNAmarin$14.55+0.9%$14.57$11.27▼$20.90$305.01M0.8175,241 shs33,155 shsANVSAnnovis Bio$1.93+1.3%$2.09$1.54▼$5.50$66.70M1.26791,920 shs822,106 shsSRZNSurrozen$24.87-4.9%$28.72$7.60▼$35.00$289.84M0.59107,026 shs103,867 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology-3.57%-5.03%+15.24%-10.43%+321.78%AMRNAmarin-0.76%-0.96%+3.22%+4.42%+27.64%ANVSAnnovis Bio-5.46%-11.60%+1.60%-29.18%-21.28%SRZNSurrozen-1.13%-3.43%-15.56%-5.90%+231.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALXOALX Oncology 2.67Moderate Buy$4.60135.29% UpsideAMRNAmarin 1.33Sell$12.00-17.75% DownsideANVSAnnovis Bio 2.25Hold$13.50590.54% UpsideSRZNSurrozen 2.80Moderate Buy$42.0067.00% UpsideCurrent Analyst Ratings BreakdownLatest ANVS, ALXO, SRZN, and AMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026AMRNAmarin Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/7/2026SRZNSurrozen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.00 ➝ $44.004/29/2026ANVSAnnovis Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026SRZNSurrozen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026SRZNSurrozen TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/20/2026AMRNAmarin Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/14/2026ANVSAnnovis Bio Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.004/2/2026AMRNAmarin Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/24/2026SRZNSurrozen Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$40.003/24/2026SRZNSurrozen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$32.00 ➝ $36.003/19/2026ALXOALX Oncology Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$5.00(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALXOALX OncologyN/AN/AN/AN/A$1.12 per shareN/AAMRNAmarin$213.65M1.43$0.36 per share40.22$21.43 per share0.68ANVSAnnovis BioN/AN/AN/AN/A$0.09 per shareN/ASRZNSurrozen$3.48M83.91N/AN/A($23.96) per share-1.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALXOALX Oncology-$101.69M-$1.49N/AN/AN/AN/A-124.06%-85.57%8/11/2026 (Estimated)AMRNAmarin-$38.80M-$0.65N/AN/AN/A-15.51%-2.99%-2.07%7/29/2026 (Estimated)ANVSAnnovis Bio-$28.85M-$1.71N/AN/AN/AN/A-318.08%-215.47%N/ASRZNSurrozen-$242.03M-$37.59N/AN/AN/A-4,810.50%-4,055.04%-154.08%8/14/2026 (Estimated)Latest ANVS, ALXO, SRZN, and AMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ANVSAnnovis Bio-$0.3950-$0.63-$0.2350-$0.63N/AN/A5/8/2026Q1 2026ALXOALX Oncology-$0.15-$0.17-$0.02-$0.17N/AN/A5/6/2026Q1 2026SRZNSurrozen-$1.0920-$11.65-$10.5580-$11.65$4.00 million$5.00 million3/23/2026Q4 2025SRZNSurrozen-$1.2875-$7.59-$6.3025-$23.88$0.66 million$0.53 million3/13/2026Q4 2025ANVSAnnovis Bio-$0.3084-$0.39-$0.0816-$0.39N/AN/A3/9/2026Q4 2025ALXOALX OncologyN/A-$0.42N/A-$0.42N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALXOALX OncologyN/AN/AN/AN/AN/AAMRNAmarinN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/ASRZNSurrozenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALXOALX Oncology0.027.217.21AMRNAmarinN/A3.482.46ANVSAnnovis BioN/A1.271.27SRZNSurrozenN/A11.9111.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALXOALX Oncology97.97%AMRNAmarin22.25%ANVSAnnovis Bio15.83%SRZNSurrozen66.57%Insider OwnershipCompanyInsider OwnershipALXOALX Oncology21.00%AMRNAmarin4.21%ANVSAnnovis Bio20.80%SRZNSurrozen31.74%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALXOALX Oncology40134.56 million106.31 millionOptionableAMRNAmarin36020.97 million20.09 millionOptionableANVSAnnovis Bio334.65 million27.44 millionOptionableSRZNSurrozen8011.61 million7.93 millionNot OptionableANVS, ALXO, SRZN, and AMRN HeadlinesRecent News About These CompaniesHead-To-Head Contrast: Relay Therapeutics (NASDAQ:RLAY) vs. Surrozen (NASDAQ:SRZN)May 21, 2026 | americanbankingnews.comWe're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn RateMay 17, 2026 | finance.yahoo.comSurrozen (SRZN) price target increased by 10.11% to 43.52May 14, 2026 | msn.comSurrozen Shareholders Support Board, Auditor and Pay PoliciesMay 14, 2026 | tipranks.comSurrozen to Present at Upcoming Healthcare Investor ConferenceMay 12, 2026 | globenewswire.comHC Wainwright Estimates Surrozen's Q2 Earnings (NASDAQ:SRZN)May 11, 2026 | marketbeat.comLifesci Capital Has Strong Forecast for Surrozen Q2 EarningsMay 11, 2026 | marketbeat.comWhat is Lifesci Capital's Forecast for Surrozen Q1 Earnings?May 8, 2026 | marketbeat.comSurrozen (NASDAQ:SRZN) Releases Earnings Results, Misses Estimates By $10.56 EPSMay 6, 2026 | marketbeat.comSurrozen Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 6, 2026 | globenewswire.comInsider Selling: Surrozen (NASDAQ:SRZN) VP Sells 1,584 Shares of StockMay 6, 2026 | insidertrades.comYang Li Sells 1,584 Shares of Surrozen (NASDAQ:SRZN) StockMay 5, 2026 | marketbeat.comSurrozen (NASDAQ:SRZN) COO Charles Williams Sells 2,036 SharesMay 5, 2026 | marketbeat.comSurrozen (NASDAQ:SRZN) CEO Craig Parker Sells 4,524 SharesMay 5, 2026 | marketbeat.comSurrozen (SRZN) Projected to Post Quarterly Earnings on FridayMay 1, 2026 | marketbeat.comSurrozen, Inc. (NASDAQ:SRZN) Sees Large Growth in Short InterestApril 29, 2026 | marketbeat.comSurrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 28, 2026 | globenewswire.comTD Cowen initiates coverage of Surrozen (SRZN) with buy recommendationApril 23, 2026 | msn.comSurrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains?April 14, 2026 | zacks.comLifeSci Capital Keeps Their Buy Rating on Surrozen (SRZN)March 29, 2026 | theglobeandmail.comSurrozen (NASDAQ:SRZN) Major Shareholder Tcg Crossover Gp Ii, Llc Purchases 15,223 SharesMarch 26, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANVS, ALXO, SRZN, and AMRN Company DescriptionsALX Oncology NASDAQ:ALXO$1.92 +0.04 (+1.85%) As of 03:21 PM Eastern This is a fair market value price provided by Massive. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Amarin NASDAQ:AMRN$14.54 +0.14 (+0.94%) As of 03:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Annovis Bio NYSE:ANVS$1.92 +0.03 (+1.32%) As of 03:20 PM Eastern This is a fair market value price provided by Massive. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Surrozen NASDAQ:SRZN$24.87 -1.29 (-4.92%) As of 03:21 PM Eastern This is a fair market value price provided by Massive. Learn more.Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
